The U.S. Supreme Court on Tuesday is poised to consider whether to restrict access to the abortion pill as President Joe Biden’s administration fights to maintain broad access to the medication in a major case that thrusts reproductive rights back on the agenda of the justices in a presidential election year.
Tag Archive for: Biden Administration
The Biden administration is sending drugmakers opening offers for the U.S. Medicare program’s first ever price negotiations on Thursday, the White House said in a statement.
The Biden administration will subject dozens of drugmakers to inflation penalties, the White House said on Thursday, in a move that would reduce out-of-pocket costs for Medicare recipients.
White House officials on Tuesday met with representatives of Sanofi, AstraZeneca, and Thermo Fisher “and urged them to work expeditiously to meet demand for immunizations this winter season through the commercial market,” the White House said in a statement.
Following a nine-month review, the Biden administration will issue a framework for the National Institutes of Health to implement so-called “march-in rights” under the Bayh-Dole Act of 1980.
Today the administration is expected to release the text of a proposed rule change to the 2008 Mental Health Parity and Addiction Equity Act that would require health plans to make changes when they are providing inadequate access to mental health care.
Texas sued the administration of U.S. President Joe Biden on Tuesday to prevent it from asking pharmacies to fill reproductive health prescriptions.
The U.S. Food and Drug Administration (FDA) will allow retail pharmacies to offer abortion pills in the United States for the first time, the agency said on Tuesday, even as more states seek to ban medication abortion.
Drugmakers including Pfizer Inc., GlaxoSmithKline PLC, Bristol Myers Squibb, AstraZeneca PLC, and Sanofi SA plan to raise prices in the United States on more than 350 unique drugs in early January, according to data analyzed by healthcare research firm 3 Axis Advisors.
The U.S. government expects its supply of COVID-19 vaccines and antiviral treatments to run out over the next year and is preparing for them to be sold via the commercial market, the Department of Health and Human Services said on Tuesday.
